1. Home
  2. BIRK vs GPCR Comparison

BIRK vs GPCR Comparison

Compare BIRK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$34.22

Market Cap

6.1B

Sector

N/A

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$46.02

Market Cap

6.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
GPCR
Founded
1774
2016
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.3B
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
BIRK
GPCR
Price
$34.22
$46.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
11
Target Price
$62.69
$103.36
AVG Volume (30 Days)
2.1M
870.4K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.71
N/A
Revenue Next Year
$14.21
N/A
P/E Ratio
$17.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.06
$13.24
52 Week High
$57.39
$94.90

Technical Indicators

Market Signals
Indicator
BIRK
GPCR
Relative Strength Index (RSI) 37.69 26.76
Support Level $33.06 $18.36
Resistance Level $42.19 $61.20
Average True Range (ATR) 1.56 3.05
MACD -0.19 -0.31
Stochastic Oscillator 20.50 9.86

Price Performance

Historical Comparison
BIRK
GPCR

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: